Abstract: An electrokinetic delivery system for personal use in self-administration of a medicament to a treatment site on an individual includes a device shaped to conform with the shape of a portion of an individual's finger from a tip thereof to a location past the first finger joint. A self-contained power source is carried by the device and a first electrode is carried by the device adjacent a distal end portion thereof and the tip of the individual's finger. The first electrode is in electrical contact with the power source. A second electrode is carried by the device for contact with the individual's finger. The second electrode is in electrical contact with the power source. Upon application of the first electrode over a treatment site with the medicament disposed between the first electrode and the treatment site and completion of an electrical circuit through the individual's body and said electrode, the device applies current for electrokinetically driving the medicament into the treatment site.

Abstract: A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymer characterized by a repeat unit having the formula: and salts thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.

Abstract: The present invention provides a method for treating pulmonary disease. More specifically, the present invention provides a method for treating diseases such as adult respiratory distress syndrome which result in oxidative stress that damages the cells of the lung. Pursuant to present invention, a method is provided that increases the intracellular glutathione levels of at least the cells of the lungs of a patient with pulmonary disease. To this end, a non-cysteine substrate that is a precursor for the intracellular synthesis of glutathione is administered to the patient.

Abstract: The present invention provides a method for reducing, or preventing, bone marrow hypoplasia in a patient at risk of, or having, same. To this end, when a glutathione intracellular stimulator is administered to such a patient, the risk of bone marrow hypoplasia is reduced or prevented. In an embodiment, the composition for stimulating the intracellular glutathione levels comprises L-2-oxothiazolidine-4-carboxylate.

Abstract: The present invention provides a method for treating atherosclerosis. The method includes the step of administering to a patient having atherosclerosis, a noncysteine, non-thiol composition that will stimulate the intracellular synthesis of glutathione. In an embodiment, the non-cysteine, non-thiol composition is L-2-oxothiazolidine-4-carboxylate. In an embodiment of the present invention, the present invention provides a method for preventing atherosclerotic lesions in a patient at risk of same. Furthermore, the present invention provides a method for preventing re-stenosis in a patient undergoing an invasive procedure to treat atherosclerosis.

Abstract: A method for stimulating the intracellular synthesis of glutathione comprising the step of administering to a mammal a therapeutically effective amount of an ester of 2-oxothiazolidine-4-carboxylate is provided.

Abstract: The present invention provides a method for treating and/or reducing ischemic reperfusion injury. To this end, in embodiment, a method for treating and/or reducing reperfusion injury is provided comprising the step of administering to a patient in danger of reperfusion injury a therapeutically effective amount of L-2-oxothiazolidine-4-carboxylic acid. In an embodiment, a method is provided for limiting an expected ischemic reperfusion injury comprising the step of administering prior to an expected ischemic event a therapeutically effective amount of L-2-oxothiazolidine-4-carboxylic acid. In a further embodiment of the present invention, a method is provided for limiting ischemic reperfusion injury comprising the step of administering to a patient after the onset of an ischemic event a therapeutically effective amount of L-2-oxothiazolidine-4-carboxylic acid.